Appointment of new CEO, Tobias Diebold
Howald, Luxembourg – Dr. Reinhold Nowak stepped down as CEO of the company on June 30, 2022. He is succeeded by Tobias Diebold, an experienced business leader who has worked as Chief Commercial Officer within the Group since 2018.
Dr. Reinhold Nowak joined Dennemeyer in 2006, led it through a phase of intense growth and developed it into an organization that today stands as one of the most important players in the Intellectual Property (IP) industry.
With 60 years of operation in the IP market, more than 20 offices worldwide and around 8,000 customers, Dennemeyer is very well established and looking forward to continuing its expansion. "I am very proud of our achievements throughout the last couple of years," said Dr. Nowak, who stepped down as CEO but will remain within the Supervisory Board, supporting the Management team.
"I am pleased that Tobias will lead the company into the next phase. I wish Tobias and the whole company all the best and a very successful future," Dr. Nowak added.
Tobias Diebold joined the company in 2018 from the LSG Group, where he served as Managing Director Sales and Products, responsible for worldwide sales and product development. "I am delighted to continue this journey with the Dennemeyer Group," Tobias Diebold said. "The Management team and I look forward to continuing Dr. Nowak's legacy and driving growth and innovation that creates value for our clients, employees and all stakeholders."
About the Dennemeyer Group
The Dennemeyer Group provides high-quality services for the protection and management of IP rights and is committed to being the first-choice partner for customers globally. Handling over three million IP rights, the Dennemeyer Group offers organizations with even the largest, most diverse IP portfolios reliable protection, administration and management of their most valuable assets. In addition to a full spectrum of IP-related legal services, Dennemeyer offers IP strategy consulting, comprehensive IP management software, IP maintenance services and cutting-edge patent search and analytics tools. For more information, visit dennemeyer.com or follow the company on LinkedIn.
Global Head of Marketing & Communications
Though Intellectual Property (IP) disputes are not uncommon in the pharmaceutical industry, the scale and prominence of this litigation are of rare magnitude.